30708-54-4Relevant articles and documents
GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
-
Page/Page column 165; 166, (2014/04/03)
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES
-
Page/Page column 41-42, (2011/07/06)
The present application relates to indole and indoline derivatives of formula (I), formula (II), formula (III), or formula (IV) wherein a, R2, R3, h, k, m, n, L, Q, X, and Z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions.
Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety
Lai, Yen-Shi,Mendoza, José S.,Jagdmann Jr., G. Erik,Menaldino, David S.,Biggers, Christopher K.,Heerding, Julia M.,Wilson, Joseph W.,Hall, Steven E.,Jiang, Jack B.,Janzen, William P.,Ballas, Lawrence M.
, p. 226 - 235 (2007/10/03)
Balanol is a potent protein kinase C (PKC) inhibitor that is structurally composed of a benzophenone diacid, a 4-hydroxybenzamide, and a perhydroazepine ring. A number of balanol analogs in which the perhydroazepine moiety is replaced have been synthesized and their biological activities evaluated against both PKC and cAMP-dependent kinase (PKA). The results suggested that the activity and the isozyme/kinase selectivity of these compounds are largely related to the conformation about this nonaromatic structural element of the molecules.